The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Anti-Obesity Drugs: A Review about Their Effects and Safety
Open accessAbstract
The current recommendations for the treatment of obese people include increased physical activity and reduced calories intake. When the behavioral approach is not sufficient, a pharmacologic treatment is recommended. In past years, numerous drugs have been approved for the treatment of obesity; however, most of them have been withdrawn from the market because of their adverse effects. In fact, amphetamine, rimonabant and sibutramine licenses have been withdrawn due to an increased risk of psychiatric disorders and non-fatal myocardial infarction or stroke. Even if orlistat is not as effective as other drugs in reducing body weight, orlistat is presently the only available choice for the treatment of obesity because of its safety for cardiovascular events and positive effects on diabetic control. Hopefully, more effective and better tolerated anti-obesity drugs will be developed through an improved understanding of the multiple mechanisms and complex physiological systems targeting appetite.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1998) · PsycEXTRA Dataset · doi:10.1037/e565682010-001 · Cited by 9,472
(1998) · PubMed · Cited by 2,737
XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study
Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.155 · Cited by 1,915
Valvular heart disease associated with fenfluramine-phentermine
Connolly, H. M., Crary, J. L., McGoon, M. D., Hensrud, D. D., Edwards, B. S., Edwards, W. D., & Schaff, H. V. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708283370901 · Cited by 1,632
Van Gaal, L. F., Rissanen, A. M., Scheen, A. J., Ziegler, O., & Rössner, S. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66374-x · Cited by 1,499
Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia
Després, J.-P., Golay, A., & Sjöström, L. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044537 · Cited by 1,392 · cited 1×
“Rimonabant was the first in a new class of agents that appears to work by selectively blocking the cannabinoid-1 receptors in the endocannabinoid system and has been extensively investigated in the Rimonabant in Obesity (RIO) program, comprised of 4 randomized, double-blinded, placebocontrolled phase 3 clinical trials…”
BackgroundPi-Sunyer, F. X., Aronne, L. J., Heshmati, H. M., Devin, J., Rosenstock, J., & RIO-North America Study Group, F. T. (2006) · JAMA · doi:10.1001/jama.295.7.761 · Cited by 1,218
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials
Christensen, R., Kristensen, P. K., Bartels, E. M., Bliddal, H., & Astrup, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61721-8 · Cited by 1,097 · cited 3×
“Food and Drug Administration (FDA) due to an increased risk of psychiatric adverse events, including depression, anxiety, and suicidal ideation [8].”
BackgroundInfluentialThe endocannabinoid system and its therapeutic exploitation
Marzo, V. D., Bifulco, M., & Petrocellis, L. D. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1495 · Cited by 1,090
Greenway, F. L., Fujioka, K., Plodkowski, R. A., Mudaliar, S., Guttadauria, M., Erickson, J., Kim, D. D., & Dunayevich, E. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60888-4 · Cited by 1,036
Overweight, Obesity, and Health Risk
(2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.7.898 · Cited by 964
Davidson, M. H., Hauptman, J., DiGirolamo, M., Foreyt, J. P., Halsted, C. H., Heber, D., Heimburger, D. C., Lucas, C. P., Robbins, D. C., Chung, J., et al. (1999) · JAMA · doi:10.1001/jama.281.3.235 · Cited by 947
Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects
James, W. P. T., Caterson, I. D., Coutinho, W., Finer, N., Van Gaal, L. F., Maggioni, A. P., Torp-Pedersen, C., Sharma, A. M., Shepherd, G. M., Rode, R. A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003114 · Cited by 943
Multicenter, placebo-controlled trial of lorcaserin for weight management.
Smith, S. R., Weissman, N. J., Anderson, C. M., Sanchez, M., Chuang, E., Stubbe, S., Bays, H., & Shanahan, W. R. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909809 · Cited by 911
Long term pharmacotherapy for obesity and overweight: updated meta-analysis
Rucker, D., Padwal, R., Li, S. K., Curioni, C., & Lau, D. C. W. (2007) · BMJ · doi:10.1136/bmj.39385.413113.25 · Cited by 801
The epidemiology of obesity: the size of the problem
James, W. P. T. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2008.01922.x · Cited by 786
Meta-Analysis: Pharmacologic Treatment of Obesity
Li, Z., Maglione, M., Tu, W., Mojica, W., Arterburn, D., Shugarman, L. R., Hilton, L., Suttorp, M., Solomon, V., Shekelle, P. G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-7-200504050-00012 · Cited by 774
Scheen, A. J., Finer, N., Hollander, P., Jensen, M. D., & Van Gaal, L. F. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69571-8 · Cited by 736
Fidler, M. C., Sanchez, M., Raether, B., Weissman, N. J., Smith, S. R., Shanahan, W. R., & Anderson, C. M. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1256 · Cited by 561
Wadden, T. A., Foreyt, J. P., Foster, G. D., Hill, J. O., Klein, S., O'Neil, P. M., Perri, M. G., Pi‐Sunyer, F. X., Rock, C. L., Erickson, J. S., et al. (2011) · Obesity · doi:10.1038/oby.2010.147 · Cited by 558
Rössner, S., Sjöström, L., Noack, R., Meinders, A. E., Noseda, G., & Study, O. B. O. T. E. O. O. (2000) · Obesity Research · doi:10.1038/oby.2000.8 · Cited by 476
Blonde, L., Klein, E. J., Han, J., Zhang, B., Mac, S. M., Poon, T. H., Taylor, K. L., Trautmann, M. E., Kim, D. D., & Kendall, D. M. (2006) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00602.x · Cited by 416
Long-term pharmacotherapy for obesity and overweight
Padwal, R. S., Rucker, D., Li, S. K., Curioni, C., & Lau, D. C. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004094.pub2 · Cited by 384
Haddock, C., Poston, W., Dill, P., Foreyt, J., & Ericsson, M. (2002) · International Journal of Obesity · doi:10.1038/sj.ijo.0801889 · Cited by 303
Addy, C., Wright, H., Van Laere, K., Gantz, I., Erondu, N., Musser, B. J., Lu, K., Yuan, J., Sanabria-Bohórquez, S. M., Stoch, A., et al. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.11.012 · Cited by 198
Astrup, A., Madsbad, S., Breum, L., Jensen, T. J., Kroustrup, J. P., & Larsen, T. M. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61525-1 · Cited by 193
Long-term Pharmacotherapy of Obesity 2000: A Review of Efficacy and Safety
Glazer, G. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.15.1814 · Cited by 170
Safety of Drug Therapies Used for Weight Loss and Treatment of Obesity
Ioannides‐Demos, L. L., Proietto, J., Tonkin, A. M., & McNeil, J. J. (2006) · Drug Safety · doi:10.2165/00002018-200629040-00001 · Cited by 166
New Drug Targets for the Treatment of Obesity
Powell, A. G., Apovian, C. M., & Aronne, L. J. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.82 · Cited by 161
Prevalence of obesity and metabolic syndrome in Korean adults
Park, H. S., Park, C. Y., Oh, S. W., & Yoo, H. J. (2008) · Obesity Reviews · doi:10.1111/j.1467-789x.2007.00421.x · Cited by 159
Self-citationBehavioral and pharmacologic therapies for obesity
Vetter, M. L., Faulconbridge, L. F., Webb, V. L., & Wadden, T. A. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.121 · Cited by 140
Torp-Pedersen, C. T., Caterson, I. D., Coutinho, W. F., Finer, N., Gaal, L. V., Maggioni, A. P., Sharma, A. M., Brisco, W., Deaton, R., Shepherd, G. M., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm217 · Cited by 130
Kaukua, J., Pekkarinen, T., Sane, T., & Mustajoki, P. (2003) · International Journal of Obesity · doi:10.1038/sj.ijo.0802379 · Cited by 124
Kang, J. G., Park, C. ‐., Kang, J., Park, Y.-W., & Park, S. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01242.x · Cited by 121
Self-citationNisoli, E., & Carruba, M. (2000) · Obesity Reviews · doi:10.1046/j.1467-789x.2000.00020.x · Cited by 116
Cercato, C., Roizenblatt, V. A., Leança, C. C., Segal, A., Lopes Filho, A. P., Mancini, M. C., & Halpern, A. (2009) · International Journal of Obesity · doi:10.1038/ijo.2009.124 · Cited by 100
Kopelman, P. G., de Groot, H. G., Rissanen, A., Rössner, S., Toubro, S., Palmer, R., Hallam, R., Bryson, A. L., & Hickling, R. I. (2009) · Obesity · doi:10.1038/oby.2009.155 · Cited by 97
Present and Future: Pharmacologic Treatment of Obesity
Glandt, M., & Raz, I. (2011) · Journal of Obesity · doi:10.1155/2011/636181 · Cited by 95
Aronne, L. J., Tonstad, S., Moreno, M., Gantz, I., Erondu, N., Suryawanshi, S., Molony, C. M., Sieberts, S. K., Nayee, J., Meehan, A. G., et al. (2010) · International Journal of Obesity · doi:10.1038/ijo.2010.21 · Cited by 92
Kaya, A., Aydın, N., Topsever, P., Filiz, M., Öztürk, A., Dağar, A., Kılınç, E., & Ekmekçioğlu, C. (2004) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2004.09.006 · Cited by 72
Proietto, J., Rissanen, A., Harp, J. B., Erondu, N., Yu, Q., Suryawanshi, S., Jones, M. E., Johnson‐Levonas, A. O., Heymsfield, S. B., Kaufman, K. D., et al. (2010) · International Journal of Obesity · doi:10.1038/ijo.2010.38 · Cited by 68
Weight Loss Produced by Tesofensine in Patients With Parkinson's or Alzheimer's Disease
Astrup, A. V., Meier, D. H., Mikkelsen, B. O., Villumsen, J., & Larsen, T. M. (2008) · Obesity · doi:10.1038/oby.2008.56 · Cited by 58
Kaukua, J., Pekkarinen, T., Sane, T., & Mustajoki, P. (2003) · International Journal of Obesity · doi:10.1038/sj.ijo.0802366 · Cited by 57
Drug Management of Obesity — Efficacy versus Safety
Astrup, A. V. (2010) · New England Journal of Medicine · doi:10.1056/nejme1004076 · Cited by 53
Orlistat and sibutramine beyond weight loss
Mannucci, E., Dicembrini, I., Rotella, F., & Rotella, C. M. (2007) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2007.03.010 · Cited by 34
Harrison‐Woolrych, M., Ashton, J., & Herbison, P. (2010) · Drug Safety · doi:10.2165/11532440-000000000-00000 · Cited by 23
Bosello, O., Carruba, M. O., Ferrannini, E., & Rotella, C. M. (2002) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/bf03327453 · Cited by 14
Efficacy and Safety of Incretin Therapy in Type 2 Diabetes: Systematic Review and Meta-analysis
Amori, R. E., Lau, J., & Pittas, A. G. (2007) · JAMA · doi:10.1001/jama.298.2.194 · Cited by 12
Practical Use of Exenatide and Pramlintide for the Treatment of Type 2 Diabetes
Meade, L. T. (2009) · Journal of Pharmacy Practice · doi:10.1177/0897190009333164 · Cited by 9
Cited by
Marrelli, M., Conforti, F., Araniti, F., & Statti, G. (2016) · Molecules · doi:10.3390/molecules21101404 · Cited by 283
Role of the vagus nerve in the development and treatment of diet‐induced obesity
de Lartigue, G. (2016) · The Journal of Physiology · doi:10.1113/jp271538 · Cited by 238
Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon
Srivastava, G., & Apovian, C. (2018) · Current Obesity Reports · doi:10.1007/s13679-018-0300-4 · Cited by 232
Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis
BonDurant, L. D., & Potthoff, M. J. (2018) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071816-064800 · Cited by 222
Onakpoya, I. J., Heneghan, C. J., & Aronson, J. K. (2016) · BMC Medicine · doi:10.1186/s12916-016-0735-y · Cited by 171
Metadata
- Authors
- Kang, J. G., & Park, C.-Y.
- Venue
- Diabetes & Metabolism Journal
- Publisher
- Korean Diabetes Association
- Published
- 2012
- Volume
- 36
- Issue
- 1
- Pages
- 13
- ISSN
- 2233-6079 (ISSN-L)
- 2233-6087
- OpenAlex
- W2101660859
- Cited by
- 593
- References
- 51
- FWCI
- 20.44
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.